1Morkve O,Laerum OD. Flow cytometric measurement of p.53 protein expression and DNA content in paraffln-embedded tissue from bronchial carcinomas[J]. Cytometry,1991,12(5) :438-444.
2Peihong S,Perry F, Expression of nm23,MMP-2,TIMP-2 in breast neoplasm in Zhengzhou Center Hospital, China[ J]. Ethiop Med J, 2007,45( 1 ) :79-83.
3Juuti A, Lundin J, Nordling S, et al. Epithelial MMP-2 expression correlates with worse prognosis in pancreatic cancer[ J]. Oncology, 2006,71 (1-2) :61-68.
6Pesta M, Topolcan O, Holubec L, et al. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples [ J ]. Antieaneer Res, 2007,27 (4) : 1863-1867.
4Maeta H,Ohgi S,Terada T,et al.Protein expression of matrix metallopro-teinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas.Virchows Arch,2001,438(2):121～128.
5Nakamura H,Ueno H,Yamashita K,et al.Enhanced production andactivation of progelatinase A mediated by membrane type Ⅰmatrixmetalloproteinase in human papillary thyroid carcinomas.Cancer Res,1999,59(2):467～473.
9Lee KH,Kim JR.Kiss-1 suppresses MMP-9 expression by activating p38 MAP kinase in human stomach cancer[J].Oncol Res,2009,18(2-3):107-116.
10Klein G,Vellenga E,Fraaije MW,et al.The possible role of matrixmetallo-proteinase (MMP)-2 and PPAR-Γ in cancer,e.g.acute leukemia[J].Crit Rev Onco I Hemat,2004,50(2):87-100.
